Newly published head-to-head data show Stiolto Respimat improved lung function across range of measures

Stiolto Respimat was compared with a European formulation of a combination of a long-acting beta agonist, salmeterol, and an inhaled corticosteroid, fluticasone propionate.

Published online in Journal of Chronic Obstructive Pulmonary Disease (COPD), these data are from the ENERGITO study, which investigated the impact of Stiolto Respimat on lung function among moderate to severe COPD patients.

"The publication of these results further demonstrates the ability of Stiolto Respimat to safely and effectively improve lung function in COPD patients," said James Donohue, MD Professor of Medicine and Former Chief of the Division of Pulmonary & Critical Care Medicine at the University of North Carolina at Chapel Hill School of Medicine. "These newly published data show a lung function improvement among COPD patients with Stiolto Respimat across a range of commonly used measures of lung function."

Long-acting beta2-adrenergic agonists, such as olodaterol, one of the active ingredients in Stiolto Respimat, increase the risk of asthma-related death. Stiolto Respimat is not indicated for asthma and should not be initiated in acutely deteriorating COPD patients or for the relief of acute symptoms. Stiolto Respimat is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product. As with other inhaled medicines, Stiolto Respimat may cause paradoxical bronchospasm that may be life-threatening. The most common adverse reactions were nasopharyngitis, cough and back pain.